Wed, March 8, 2023

Jason Gerberry Downgraded (CARA) to Sell and Decreased Target to $6 on, Mar 8th, 2023

Jason Gerberry of B of A Securities, Downgraded "Cara Therapeutics, Inc." (CARA) to Sell and Decreased Target from $13 to $6 on, Mar 8th, 2023.

Jason has made no other calls on CARA in the last 4 months.



There are 5 other peers that have a rating on CARA. Out of the 5 peers that are also analyzing CARA, 0 agree with Jason's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Jason


  • Daniel Wolle of "JP Morgan" Maintained at Buy with Decreased Target to $16 on, Tuesday, March 7th, 2023
  • David Amsellem of "Piper Sandler" Maintained at Buy with Decreased Target to $13 on, Tuesday, March 7th, 2023
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $22 on, Tuesday, March 7th, 2023
  • Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, March 7th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $25 on, Tuesday, March 7th, 2023